PDS Biotechnology (NASDAQ:PDSB) Issues Earnings Results

PDS Biotechnology (NASDAQ:PDSB) issued its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05), FiscalAI reports.

PDS Biotechnology Stock Down 3.6%

NASDAQ PDSB traded down $0.01 on Thursday, hitting $0.23. 4,339,664 shares of the stock were exchanged, compared to its average volume of 958,785. PDS Biotechnology has a fifty-two week low of $0.22 and a fifty-two week high of $1.55. The company has a 50-day moving average price of $0.82 and a 200-day moving average price of $0.86. The company has a quick ratio of 2.26, a current ratio of 2.26 and a debt-to-equity ratio of 2.73. The company has a market cap of $13.04 million, a PE ratio of -0.35 and a beta of 1.62.

Hedge Funds Weigh In On PDS Biotechnology

Large investors have recently bought and sold shares of the business. Armistice Capital LLC acquired a new stake in PDS Biotechnology in the fourth quarter valued at $2,182,000. Squarepoint Ops LLC lifted its stake in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after purchasing an additional 156,662 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in PDS Biotechnology by 117.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares in the last quarter. Susquehanna International Group LLP increased its stake in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in PDS Biotechnology during the second quarter worth approximately $92,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PDSB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research note on Wednesday, April 15th. Finally, Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.